<ruby id="bdzv7"><p id="bdzv7"></p></ruby>
          <output id="bdzv7"><strike id="bdzv7"></strike></output><menuitem id="bdzv7"><strike id="bdzv7"><th id="bdzv7"></th></strike></menuitem>

          <mark id="bdzv7"><ruby id="bdzv7"></ruby></mark>

          <mark id="bdzv7"><ruby id="bdzv7"></ruby></mark>

            <listing id="bdzv7"></listing>

                <listing id="bdzv7"><span id="bdzv7"></span></listing>
                <dfn id="bdzv7"></dfn>

                  [1]蔣萌,張明.抗VEGF藥物玻璃體內注射誘發感染性眼內炎的研究現狀[J].眼科新進展,2023,43(7):580-584.[doi:10.13389/j.cnki.rao.2023.0117]
                   JIANG Meng,ZHANG Ming.The occurrence of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor drugs[J].Recent Advances in Ophthalmology,2023,43(7):580-584.[doi:10.13389/j.cnki.rao.2023.0117]
                  點擊復制

                  抗VEGF藥物玻璃體內注射誘發感染性眼內炎的研究現狀/HTML
                  分享到:

                  《眼科新進展》[ISSN:1003-5141/CN:41-1105/R]

                  卷:
                  43卷
                  期數:
                  2023年7期
                  頁碼:
                  580-584
                  欄目:
                  文獻綜述
                  出版日期:
                  2023-07-05

                  文章信息/Info

                  Title:
                  The occurrence of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor drugs
                  作者:
                  蔣萌張明
                  610041 四川省成都市,四川大學華西醫院眼科(蔣萌,張明);621000 四川省綿陽市,綿陽萬江眼科醫院(蔣萌)
                  Author(s):
                  JIANG Meng12ZHANG Ming1
                  1.Department of Ophthalmology,West China Hospital of Sichuan University,Chengdu 610041,Sichuan Province,China
                  2.Mianyang Wanjiang Ophthalmology Hospital,Mianyang 621000,Sichuan Province,China
                  關鍵詞:
                  玻璃體內注藥抗血管內皮生長因子感染性眼內炎
                  Keywords:
                  intravitreal injection anti-vascular endothelial growth factor infectious endophthalmitis
                  分類號:
                  R771.2
                  DOI:
                  10.13389/j.cnki.rao.2023.0117
                  文獻標志碼:
                  A
                  摘要:
                  抗血管內皮生長因子(VEGF)已被廣泛應用于治療濕性年齡相關性黃斑變性、視網膜靜脈阻塞性黃斑水腫等各類眼科疾病。玻璃體內注射抗VEGF藥物通常是安全有效的,然而感染性眼內炎仍然是一種潛在的嚴重并發癥。雖然該病發生率低,但隨著藥物注射數量的增加,感染性眼內炎發生的概率也逐漸增加。因此,本文就玻璃體內抗VEGF藥物注射后感染性眼內炎的發病率、致病菌、發生機制、臨床特征、風險因素、治療及預后進行綜述。
                  Abstract:
                  Anti-vascular endothelial growth factor (VEGF) drugs have been widely used to treat wet age-related macular degeneration,retinal vein occlusion-associated macular edema,and other ophthalmic diseases.Intravitreal injection of anti-VEGF drugs is normally safe and effective; however,infectious endophthalmitis is still a potentially devastating complication.Its incidence is low but goes up with the increase in the number of injections of these drugs.Therefore,this article reviews the incidence rate,pathogenic bacteria,pathogenesis,clinical characteristics,risk factors,treatment and prognosis of infectious endophthalmitis after intravitreal injection of anti-VEGF drugs.

                  參考文獻/References:

                  [1] GRZYBOWSKI A,TOLD R,SACU S,BANDELLO F,MOISSEIEV E,LOEWENSTEIN A,et al.2018 update on intravitreal injections:Euretina expert consensus recommendations[J].Ophthalmologica,2018,239(4):181-193.
                  [2] STOREY P P,PATEL D,GARG S.Endophthalmitis following intravitreal injection of anti-vascular endothelial growth factor agents[J].Can J Ophthalmol,2020,55(4):286-292.
                  [3] 賴江峰,彭靜,藍誠紅,余兆敏,李達佑.雷珠單抗玻璃體腔注射聯合玻璃體切割術治療玻璃體積血療效觀察[J].新鄉醫學院學報,2020,37(7):691-695.
                  LAI J F,PENG J,LAN C H,YU Z M,LI D Y.Therapeutic effect of intravitreal injection of leizumab combined with vitrectomy in the treatment of vitreous hemorrhage[J].J Xin-xiang Med Univ,2020,37(7):691-695.
                  [4] WADE C I,WHITESCARVER T D,ASHCROFT C R,HOBBS S D,PURT B,REDDY A K,et al.Endophthalmitis:a bibliographic review[J].Int Ophthalmol,2021,41(12):4151-4161.
                  [5] BAUDIN F,BENZENINE E,MARIET A S,BRON A M,DAIEN V,KOROBELNIK J F,et al.Association of acute endophthalmitis with intravitreal injections of corticosteroids or anti-vascular growth factor agents in a nationwide study in France[J].JAMA Ophthalmol,2018,136(12):1352-1358.
                  [6] SCHARGUS M,FRINGS A.Issues with intravitreal administration of anti-VEGF drugs[J].Clin Ophthalmol,2020,14:897-904.
                  [7] MCCANNEL C A.Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents:causative organisms and possible prevention strategies[J].Retina,2011,31(4):654-661.
                  [8] MERANI R,HUNYOR A P.Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review[J].Int J Retina Vitreous,2015,1:9.
                  [9] KISS S,DUGEL P U,KHANANI A M,BRODER M S,CHANG E,SUN G H,et al.Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections:a USA claims analysis[J].Clin Ophthalmol,2018,12:1625-1635.
                  [10] PATEL S N,GANGAPUTRA S,STERNBERG P J,KIM S J.Prophylaxis measures for postinjection endophthalmitis[J].Surv Ophthalmol,2020,65(4):408-420.
                  [11] COX J T,ELIOTT D,SOBRIN L.Inflammatory complications of intravitreal anti-VEGF Injections[J].J Clin Med,2021,10(5):981.
                  [12] BUSCH C,IGLICKI M,OKADA M,GABRIELLE P H,COHEN S,MARIUSSI M,et al.Causative pathogens of endophthalmitis after intravitreal anti-VEGF injection:an international multicenter study[J].Ophthalmologica,2019,241(4):211-219.
                  [13] MCCANNEL C A.Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents:causative organisms and possible prevention strategies[J].Retina,2011,31(4):654-661.
                  [14] FILETA J B,SCOTT I U,FLYNN H W J.Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents[J].Ophthalmic Surg Lasers Imaging Retina,2014,45(2):143-149.
                  [15] MISHRA C,LALITHA P,RAMESHKUMAR G,AGRAWAL R,BALNE P K,ISWARYA M,et al.Incidence of endophthalmitis after intravitreal injections: risk factors,microbiology profile,and clinical outcomes[J].Ocul Immunol Inflamm,2018,26(4):559-568.
                  [16] RAYESS N,RAHIMY E,STOREY P,SHAH C P,WOLFE J D,CHEN E,et al.Postinjection endophthalmitis rates and characteristics following intravitreal Bevacizumab,Ranibizumab,and Aflibercept[J].Am J Ophthalmol,2016,165:88-93.
                  [17] LI A L,WYKOFF C C,WANG R,CHEN E,BENZ M S,FISH R H,et al.Endophthalmitis after intravitreal injection:role of prophylactic topical ophthalmic antibiotics[J].Retina,2016,36(7):1349-1356.
                  [18] CHEN E,LIN M Y,COX J,BROWN D M.Endophthalmitis after intravitreal injection:the importance of viridans streptococci[J].Retina,2011,31(8):1525-1533.
                  [19] SIMUNOVIC M P,RUSH R B,HUNYOR A P,CHANG A A.Endophthalmitis following intravitreal injection versus endophthalmitis following cataract surgery:clinical features,causative organisms and post-treatment outcomes[J].Br J Ophthalmol,2012,96(6):862-866.
                  [20] CHEN E,LIN M Y,COX J,BROWN D M.Endophthalmitis after intravitreal injection:the importance of viridans streptococci[J].Retina,2011,31(8):1525-1533.
                  [21] SHEYMAN A T,COHEN B Z,FRIEDMAN A H,ACKERT J M.An outbreak of fungal endophthalmitis after intravitreal injection of compounded combined bevacizumab and triamcinolone[J].JAMA Ophthalmol,2013,131(7):864-869.
                  [22] DECARO J J,TA C N,HO H K,CABAEL L,HU N,SANISLO S R,et al.Bacterial contamination of ocular surface and needles in patients undergoing intravitreal injections[J].Retina,2008,28(6):877-883.
                  [23] KIM S J,TOMA H S,MIDHA N K,CHERNEY E F,RECCHIA F M,DOHERTY T J.Antibiotic resistance of conjunctiva and nasopharynx evaluation study:a prospective study of patients undergoing intravitreal injections[J].Ophthalmology,2010,117(12):2372-2378.
                  [24] BISORCA-GASSENDORF L,BODEN K T,SZURMAN P,AL-NAWAISEH S,RICKMANN A,JANUSCHOWSKI K.Postoperative endophthalmitis-a review of literature[J].Ophthalmologe,2021,118(3):210-218.
                  [25] SINGH R,DAVOUDI S,NESS S.Preventive factors,diagnosis,and management of injection- related endophthalmitis:a literature review[J].Graefes Arch Clin Exp Ophthalmol,2022,260(8):2399-2416.
                  [26] SACHDEVA M M,MOSHIRI A,LEDER H A,SCOTT A W.Endophthalmitis following intravitreal injection of anti-VEGF agents:long-term outcomes and the identification of unusual micro-organisms[J].J Ophthalmic Inflamm Infect,2016,6(1):2.
                  [27] CUNHA A M,IGLSIAS M M,ROCHA-SOUSA A,FALCO-REIS F,FALCO M.Endophthalmitis following intravitreal injection,cataract surgery,and vitrectomy:clinical features and visual outcomes[J].J Ophthalmol,2021,20,2021:9985821.
                  [28] RAMOS M S,XU L T,SINGURI S,CASTILLO TAFUR J C,AREPALLI S,EHLERS J P,et al.Patient-reported complications after intravitreal injection and their predictive factors[J].Ophthalmol Retina,2021,5(7):625-632.
                  [29] BAVINGER J C,YU Y,VANDERBEEK B L.Comparative risk of endophthalmitis after intravitreal injection with bevacizumab,aflibercept,and ranibizumab[J].Retina,2019,39(10):2004-2011.
                  [30] MCDERMOTT A M.Antimicrobial compounds in tears[J].Exp Eye Res,2013,117:53-61.
                  [31] LI T,SUN J,MIN J,ZHOU S,ZHU X,JIA H,et al.Safety of receiving anti-vascular endothelial growth factor intravitreal injection in office-based vs.operating room settings:a meta-analysis[J].JAMA Ophthalmol,2021,139(10):1080-1088.
                  [32] KIM S J,TOMA H S.Ophthalmic antibiotics and antimicrobial resistance a randomized,controlled study of patients undergoing intravitreal injections[J].Ophthalmology,2011,118(7):1358-1363.
                  [33] MENCHINI F,TONEATTO G,MIELE A,DONATI S,LANZETTA P,VIRGILI G.Antibiotic prophylaxis for preventing endophthalmitis after intravitreal injection:a systematic review[J].Eye(Lond),2018,32(9):1423-1431.
                  [34] BAUDIN F,BENZENINE E,MARIET A S,GHEZALA I B,BRON A M,DAIEN V,et al.Topical antibiotic prophylaxis and intravitreal injections: impact on the incidence of acute endophthalmitis-a nationwide study in France from 2009 to 2018[J].Pharmaceutics,2022,14(10):2133.
                  [35] REIBALDI M,PULVIRENTI A,AVITABILE T,BONFIGLIO V,RUSSO A,MARIOTTI C,et al.Pooled estimates of incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents with and without topical antibiotic prophylaxis[J].Retina,2018,38(1):1-11.
                  [36] STOREY P P,TAUQEER Z,YONEKAWA Y,TODORICH B,WOLFE J D,SHAH S P,et al.The impact of prefilled syringes on endophthalmitis following intravitreal injection of ranibizumab[J].Am J Ophthalmol,2019,199:200-208.
                  [37] SCHARGUS M,FRINGS A.Issues with intravitreal administration of anti-VEGF drugs[J].Clin Ophthalmol,2020,14:897-904.
                  [38] 李娜,石芊,高笠雄,曹利群.玻璃體腔注射術后眼內炎的臨床分析[J].眼科學報,2021,36(5):343-346.
                  LI N,SHI Q,GAO L X,CAO L Q.Clinical analysis on endophthalmitis after intravitreal injection[J].Eye Sci,2021,36(5):343-346.
                  [39] GREEN-SIMMS A E,EKDAWI N S,BAKRI S J.Survey of intravitreal injection techniques among retinal specialists in the United States[J].Am J Ophthalmol,2011,151(2):329-332.
                  [40] BUCKLEY T,DUDLEY S M,DONOWITZ L G.Defining unnecessary disinfection procedures for single-dose and multiple-dose vials[J].Am J Crit Care,1994,3(6):448-451.
                  [41] HILLIARD J G,CAMBRONNE E D,KIRSCH J R,AZIZ M F.Barrier protection capacity of flip-top pharmaceutical vials[J].J Clin Anesth,2013,25(3):177-180.
                  [42] PATEL S N,HSU J,SIVALINGAM M D,CHIANG A,KAISER R S,MEHTA S,et al.The impact of physician face mask use on endophthalmitis after intravitreal anti-vascular endothelial growth factor injections[J].Am J Ophthalmol,2021,222:194-201.
                  [43] GARG S J,DOLLIN M,HSU J,STOREY P,VANDER J F.Effect of a strict‘no-talking’policy during intravitreal injection on post-injection endophthalmitis[J].Ophthalmic Surg Lasers Imaging Retina,2015,46(10):1028-1034.
                  [44] FRIEDMAN D A,MASON J O,EMOND T,MCGWIN G J.Povidone-iodine contact time and lid speculum use during intravitreal injection[J].Retina,2013,33(5):975-981.
                  [45] SPEAKER M G,MENIKOFF J A.Prophylaxis of endophthalmitis with topical povidone-iodine[J].Ophthalmology,1991,98(12):1769-1775.
                  [46] GEERLINGS S E,HOEPELMAN A I.Immune dysfunction in patients with diabetes mellitus(DM)[J].FEMS Immunol Med Microbiol,1999,26(3-4):259-265.
                  [47] RAYESS N,RAHIMY E,SHAH C P,WOLFE J D,CHEN E,DECROOS F C,et al.Incidence and clinical features of post-injection endophthalmitis according to diagnosis[J].Br J Ophthalmol,2016,100(8):1058-1061.
                  [48] 中華醫學會眼科學分會眼底病學組,中華醫學會眼科學分會白內障及屈光手術學組中華醫學會眼科學分會眼外傷學組,中華醫學會眼科學分會青光眼學組.中國眼科手術后感染性眼內炎診療專家共識(2022年)[J].中華眼科雜志,2022,58(7):487-499.
                  Chinese Vitreo-Retina Society of Chinese Medical Association,Chinese Cataract And Refractive Surgery Society,China Ocular Trauma Society,Glaucoma Group of Ophthalmology Branch of Chinese Medical Association.Chinese expert consensus on the diagnosis and management of infectious endophthalmitis after ophthalmic surgery(2022)[J].Chin J Ophthalmol,2022,58(7):487-499.
                  [49] STOREY P,DOLLIN M,PITCHER J,REDDY S,VOJTKO J,VANDER J,et al.Post-injection endophthalmitis study team.the role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection[J].Ophthalmology,2014,121(1):283-289.
                  [50] SRIDHAR J,YONEKAWA Y,KURIYAN A E,JOSEPH A,THOMAS B J,LIANG M C,et al.Microbiologic spectrum and visual outcomes of acute-onset endophthalmitis undergoing therapeutic pars plana vitrectomy[J].Retina,2017,37(7):1246-1251.

                  相似文獻/References:

                  [1]欒蘭 姚勇.濕性年齡相關性黃斑變性的治療進展[J].眼科新進展,2013,33(4):000.
                  [2]劉李平 宋徽 肖云 曹小鵬 白潤 陳珍.玻璃體注射雷珠單抗治療缺血型視網膜中央靜脈阻塞的臨床觀察[J].眼科新進展,2013,33(11):000.
                  [3]劉晶晶,劉子揚,彭清.滲出型年齡相關性黃斑變性的抗血管內皮生長因子治療進展[J].眼科新進展,2015,35(1):084.[doi:10.13389/j.cnki.rao.2015.0024]
                   LIU Jing-Jing,LIU Zi-Yang,PENG Qing.Recent advances in anti-vascular endothelial growth factor for exudative age-related macular degeneration[J].Recent Advances in Ophthalmology,2015,35(7):084.[doi:10.13389/j.cnki.rao.2015.0024]
                  [4]夏松,陳有信.視網膜靜脈阻塞繼發黃斑水腫的抗VEGF藥物治療進展[J].眼科新進展,2016,36(11):1093.[doi:10.13389/j.cnki.rao.2016.0292]
                   XIA Song,CHEN You-Xin.Research progress on anti-VEGF drugs for macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(7):1093.[doi:10.13389/j.cnki.rao.2016.0292]
                  [5]李松峰,鄧光達,劉敬花,等.視網膜下液引流聯合玻璃體內注射抗血管內皮生長因子藥物治療重度滲出性視網膜脫離Coats病的臨床療效[J].眼科新進展,2017,37(6):569.[doi:10.13389/j.cnki.rao.2017.0144]
                   LI Song-Feng,DENG Guang-Da,LIU Jing-Hua,et al.Subretinal fluid drainage combined with intravitreal injection of anti-vascular endothelial growth factor in treatment of severe exudative retinal detachment Coats disease[J].Recent Advances in Ophthalmology,2017,37(7):569.[doi:10.13389/j.cnki.rao.2017.0144]
                  [6]呂亞男,宮媛媛.抗血管內皮生長因子(VEGF)治療與視網膜下纖維化研究進展[J].眼科新進展,2017,37(6):583.[doi:10.13389/j.cnki.rao.2017.0148]
                   LV Ya-Nan,GONG Yuan-Yuan.Anti-VEGF therapy and subretinal fibrosis[J].Recent Advances in Ophthalmology,2017,37(7):583.[doi:10.13389/j.cnki.rao.2017.0148]
                  [7]許曉璇,胡裕翔,程藝,等.早產兒視網膜病變抗血管內皮生長因子藥物治療新進展[J].眼科新進展,2018,38(9):883.[doi:10.13389/j.cnki.rao.2018.0209]
                   XU Xiao-Xuan,HU Yu-Xiang,CHENG Yi,et al.New advances in anti-vascular endothelial growth factor drug therapy for retinopathy of prematurity[J].Recent Advances in Ophthalmology,2018,38(7):883.[doi:10.13389/j.cnki.rao.2018.0209]
                  [8]朱婷婷,王權,姜彩輝.糖尿病黃斑水腫治療新進展[J].眼科新進展,2019,39(3):296.[doi:10.13389/j.cnki.rao.2019.0067]
                   ZHU Ting-Ting,WANG Quan,JIANG Cai-Hui.Recent research advances in the treatment of diabetic macular edema[J].Recent Advances in Ophthalmology,2019,39(7):296.[doi:10.13389/j.cnki.rao.2019.0067]
                  [9]宋晶,熊杰.康柏西普玻璃體內注射治療特發性脈絡膜新生血管[J].眼科新進展,2020,40(2):169.[doi:10.13389/j.cnki.rao.2020.0040]
                   SONG Jing,XIONG Jie.Intravitreal injection of Conbercept in treatment of patients with idiopathic choroidal neovascularization[J].Recent Advances in Ophthalmology,2020,40(7):169.[doi:10.13389/j.cnki.rao.2020.0040]
                  [10]羅曼,陳曉隆.新生血管性年齡相關性黃斑變性患者玻璃體內注射抗血管內皮生長因子藥物治療進展[J].眼科新進展,2020,40(6):582.[doi:10.13389/j.cnki.rao.2020.0134]
                   LUO Man,CHEN Xiaolong.Progress in treatment of neovascular age-related macular degeneration with intravitreal injection of anti-VEGF drugs[J].Recent Advances in Ophthalmology,2020,40(7):582.[doi:10.13389/j.cnki.rao.2020.0134]

                  備注/Memo

                  備注/Memo:
                  科技部國家重點研發計劃(編號:2018YFC1106103);四川省醫學青年創新科研課題(編號:Q21096);綿陽市衛生健康委員會科研課題(編號:202127)
                  更新日期/Last Update: 2023-07-05
                  做做受视频播放试看30分钟_国产成人美女视频网站_亚洲成在人网站天堂日本_最新亚洲人成无码www

                          <ruby id="bdzv7"><p id="bdzv7"></p></ruby>
                          <output id="bdzv7"><strike id="bdzv7"></strike></output><menuitem id="bdzv7"><strike id="bdzv7"><th id="bdzv7"></th></strike></menuitem>

                          <mark id="bdzv7"><ruby id="bdzv7"></ruby></mark>

                          <mark id="bdzv7"><ruby id="bdzv7"></ruby></mark>

                            <listing id="bdzv7"></listing>

                                <listing id="bdzv7"><span id="bdzv7"></span></listing>
                                <dfn id="bdzv7"></dfn>